Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Core Insights - Fennec Pharmaceuticals reported a record net product sales of $12.5 million for Q3 2025, representing a 79% year-over-year growth, marking the strongest quarter in the company's history [1][8] - The company achieved positive cash flow from operations, with cash and cash equivalents increasing to $22 million as of September 30, 2025 [1][8] - The preliminary results of the clinical trial STS-J01 in Japan are expected in Q4 2025, which could lead to potential registration and partnership opportunities for PEDMARK if results are favorable [1][7] Financial Performance - Net product sales for Q3 2025 were approximately $12.5 million, up from $7.0 million in Q3 2024, indicating significant growth [8][10] - Selling and marketing expenses increased to $5.2 million in Q3 2025 from $4.4 million in Q2 2025 and $4.6 million in Q3 2024 [8] - General and administrative expenses decreased slightly to $6.8 million in Q3 2025 from $7.0 million in Q2 2025 [8] Business Developments - The adoption of PEDMARK has accelerated within key oncology provider networks, reflecting growing confidence in its clinical value [7] - The company is engaged with key opinion leaders and has multiple investigator-initiated studies under review, which are expected to strengthen its clinical and commercial foundation [7] - Fennec's strategy to enhance its commercial organization and drive broader adoption of PEDMARK is showing tangible results [2][7] Upcoming Events - Fennec Pharmaceuticals will host one-on-one investor meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 [4]